Clinicopathological Characteristics and Prognostic Prediction in Pseudomyxoma Peritonei Originating From Mucinous Ovarian Cancer

Fengxian Fu; Xulan Ma; Yiyan Lu; Hongbin Xu; Ruiqing Ma

doi:10.3389/fonc.2021.641053

Clinicopathological Characteristics and Prognostic Prediction in Pseudomyxoma Peritonei Originating From Mucinous Ovarian Cancer

Front Oncol. 2021 Apr 21:11:641053. doi: 10.3389/fonc.2021.641053. eCollection 2021.

Authors

Fengxian Fu¹, Xulan Ma¹, Yiyan Lu², Hongbin Xu³, Ruiqing Ma³

Affiliations

¹ Department of Gynecology, Aerospace Center Hospital, Beijing, China.
² Department of Pathology, Aerospace Center Hospital, Beijing, China.
³ Department of Myxoma, Aerospace Center Hospital, Beijing, China.

Abstract

Objective: To describe the clinicopathological characteristics of mucinous ovarian cancer (MOC)-derived pseudomyxoma peritonei (PMP) and identify prognostic factors for survival.

Methods: Medical records from patients with MOC-derived PMP who attended the Aerospace Center Hospital, Beijing, China between January 2009, and December 2019 were retrospectively reviewed. Survival analysis was performed with the Kaplan-Meier method, the log-rank test, and a Cox proportional hazards model.

Results: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for PMP originating from MOC were performed on 22 patients, who had a median age of 52 years at the time of surgery. At the last follow-up in June 2020, 9 (41%) patients were still alive. Median OS was 12 months (range, 1 to 102 months), and the 2-, 3-, and 5-year survival rates were 23, 9, and 5%, respectively.

Conclusion: Histopathologic subtype and PCI may be applied as predictors of prognosis in patients with MOC-derived PMP. Patients with high-grade disease could benefit from completeness of cytoreduction (CCR) 0/1.

Keywords: cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC); mucinous ovarian cancer; overall survival (OS); prognostic prediction; pseudomyxoma peritonei.